Certis Oncology Solutions received patent approval for its predictive AI/ML platform, CertisAI™, designed to forecast drug response using gene expression signatures. This patent reinforces Certis’s intellectual property and underscores the platform’s unique capabilities in predicting drug efficacy and resistance. The USPTO allowance strengthens Certis’s position in the precision oncology field and highlights the platform’s potential to reshape drug development.
This development is crucial for the biopharmaceutical industry because CertisAI democratizes access to advanced AI/ML tools. Smaller companies, often lacking the resources to develop such technologies in-house, now gain access to a powerful platform for optimizing preclinical studies, informing clinical trial design, and exploring regulatory strategies. This could lead to a more efficient and cost-effective drug development process across the industry, potentially accelerating the delivery of novel cancer therapies to patients.
CertisAI integrates diverse datasets, including drug features, gene expression biomarkers, and drug response data. It utilizes patient-derived xenografts (PDXs) for model validation, enhancing the clinical relevance of its predictions. The patent protection extends until March 2043, providing Certis with a substantial period to capitalize on its innovation. Launched in April 2024 as an extension of Certis’s preclinical services, the platform empowers researchers to make data-driven decisions in early drug development.
This patent solidifies Certis’s position as a key player in the precision oncology landscape. The extended patent protection offers a significant competitive advantage and allows Certis to further develop and refine its AI/ML capabilities. Ultimately, this could accelerate the development of more effective and targeted cancer treatments, benefiting both pharmaceutical companies and patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
